Living with both type 2 diabetes and heart failure creates a complex challenge for managing daily health. New data helps clarify which medications might offer the best protection for the heart. A large analysis of over 13,000 patients compared several types of drugs, including SGLT2 inhibitors and GLP-1RAs, against a placebo.
The results show that both SGLT2 inhibitors and GLP-1RAs significantly reduced the risk of heart failure complications. Specifically, SGLT2 inhibitors lowered the risk of heart failure worsening and hospitalizations. While both types of drugs performed well, the study found no significant difference in effectiveness between SGLT2 inhibitors and GLP-1RAs.
While these medications show strong promise for heart health, some results are still unclear. For example, while SGLT2 inhibitors showed a trend toward reducing all-cause death, the result was not statistically significant. Additionally, the data did not show a clear, significant benefit for kidney outcomes. More research is needed to confirm exactly how these drugs affect kidney health.
